BioNexus Gene Lab vs Personalis
BGLC and PSNL side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BGLC and PSNL compare
Personalis is the larger company, worth 697 times as much as BioNexus Gene Lab ($1.7B against $2.4M).
Personalis grew revenue faster over the last twelve months (16.9% versus −67.3% for BioNexus Gene Lab).
BioNexus Gene Lab keeps more of each dollar of sales as profit, with a net margin of −82.4% compared with −148% at Personalis.
BioNexus Gene Lab scores higher on the StockData Score (8 against 5 for Personalis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BGLC | PSNL |
|---|---|---|
| Size and price | ||
| Market cap | $2.4M | $1.7B |
| Share price | $0.821 | $15.71 |
| Change, 1 year | −83.0% | 96.1% |
| Change, 5 years | −99.6% | 5.1% |
| Beta (5Y) | 0.87 | 1.87 |
| Employees | 6 | 260 |
| StockData Score | ||
| Total score | 8 (better) | 5 |
| Valuation score | 3 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.8× (better) | 20.8× |
| P/B | 0.3× (better) | 7.9× |
| FCF yield | −35.4% | −6.4% (better) |
| Fair value | $7.45 | $3.28 |
| Margin of safety | 89.0% (better) | −379% |
| Growth | ||
| Revenue growth (TTM) | −67.3% | 16.9% (better) |
| Revenue growth, 5Y average | −8.2% | −2.4% (better) |
| Profitability | ||
| Gross margin | 12.3% | 16.7% (better) |
| Operating margin | −81.8% (better) | −157% |
| Net margin | −82.4% (better) | −148% |
| FCF margin | −27.3% (better) | −133% |
| Return on equity | −33.7% (better) | −62.1% |
| Return on invested capital | −32.3% (better) | −465% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | – | −684.0× |
| Current ratio | 6.08 (better) | 4.53 |
| Altman Z-score | 0.32 | 8.83 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | −8.0% |
| Shareholder yield | 0.00% (better) | −8.0% |
| Ownership | ||
| Held by institutions | 0.49% | 79.6% |
| Held by insiders | 31.0% | 15.0% |
| Insider net buying, 12 months | – | −$6.9M |
| Short interest, % of float | 0.16% | 7.4% |
Go deeper
- BGLC stock overview
- BGLC income statement
- BGLC valuation and score
- PSNL stock overview
- PSNL income statement
- PSNL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.